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Abstract
Encapsidation of adenovirus DNA involves specific interactions between cis-acting genomic DNA sequences and trans-acting proteins.
The cis-acting packaging domain located near the left inverted terminal repeat is composed of a series of redundant but not functionally
equivalent motifs. Such motifs are made up of the consensus sequence 5-TTTGN8CG-3 and 5-TTTG/A-3 in human adenovirus 5
(HAV-5) and canine adenovirus-2 (CAV-2), respectively. To gain comparative insight into adenovirus encapsidation, we examined the
packaging domain of porcine adenovirus-3 (PAV-3). Using deletion mutants, we localized the PAV-3 packaging domain to 319 bp (nt 212
to 531), which contains six cis-acting elements. However, this domain does not contain the consensus motifs identified in HAV-5. In
addition, consensus motif found in CAV-2 is present only once in PAV-3. Instead, PAV-3 packaging domain appears to contain AT/GC-rich
sequences. The packaging motifs of PAV-3, which are functionally redundant but not equivalent, are located at the left end of the genome.
© 2003 Elsevier Inc. All rights reserved.
Since adenoviruses have become popular as vectors for
the delivery of foreign genes in mammalian cells, constant
attempts are being made to develop adenovirus vectors with
improved capacity, safety, and efficacy (Russell, 2000). To
achieve this, detailed knowledge of biology of adenovirus
including mechanisms of virus particle assembly and viral
DNA packaging is necessary. Although analysis of adeno-
virus particle assembly has been the focus of many studies
(D’Halluin et al., 1978a, 1978b, 1980; Edvardsson et al.,
1976, 1978), little is known about the basic mechanism of
encapsidation of adenovirus DNA.
Earlier studies using temperature-sensitive mutants and
pulse-chase kinetics experiments have established that ade-
novirus DNA is inserted into preformed, empty capsids late
in the viral life cycle (D’Halluin, 1995). Other studies on
viral incomplete particles containing DNA molecules of
subgenomic length suggested that DNA packaging occurs in
a polar fashion from left to right (Daniell, 1976; Tibbetts,
1977; Hammarskjold and Winberg, 1980; Kosturko et al.,
1982; Robinson and Tibbetts, 1984). Subsequent studies
suggested that a cis-acting packaging domain located in the
left end of the adenovirus genome is required for the selec-
tive encapsidation of viral DNA (Grable and Hearing, 1990,
1992; Hearing et al., 1987). However, the position and the
orientation of this packaging domain is not strict as long as
it is within first or last 600 bp (Hasson et al., 1989; Hearing
and Shenk, 1983; Hearing et al., 1987).
The cis-acting packaging domain in human adenovirus
type 5 (HAV-5) is located in the left end 380 bp (Hearing et
al., 1987). It contains at least seven functionally redundant
“A-repeat” domains (Grable and Hearing, 1990, 1992), four
of which (AI, AII, AV, and AVI) are most dominant
(Schmid and Hearing, 1997). Mutational analysis of A-re-
peat consensus sequence (5-TTTGN8CG-3) suggested that
sequence as well as the spacing (N8) of two elements 5-
TTTG-3 and 5-CG-3 are critical for maximum packaging
capacity (Schmid and Hearing, 1997). In addition to cis-
acting sequences, a number of viral and/or cellular proteins
are thought to be involved in adenovirus DNA packaging
(Fujisawa and Hearing, 1994; Grable and Hearing, 1992;
Schmid and Hearing, 1995). Schmid and Hearing have
detected some cellular proteins binding to the packaging
sequences (Schmid and Hearing, 1997). Among viral pro-
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teins, the 52/55-kDa and IVa2 proteins have been shown to
date to be required for viral DNA packaging (Gustin and
Imperiale, 1998; Hasson et al., 1989; Zhang et al., 2000,
2001). Interaction of IVa2 with the different components of
the DNA packaging machinery has been shown to be sero-
type specific (Zhang et al., 2000, 2001). Although identity
of some of these proteins is becoming known, the nature of
interactions between different components of the packaging
machinery remains unclear.
Recently, cis-acting packaging domain of canine adeno-
virus-2 (CAV-2) has been identified (Soudais et al., 2001).
Similar to HAV-5 (Schmid and Hearing, 1997), cis-acting
packaging motifs of CAV-2 are located in the left end of the
genome and are functionally redundant (Soudais et al.,
2001). However, the primary sequence of packaging motifs
required for packaging CAV-2 or HAV-5 DNA appears to
be different (Schmid and Hearing, 1997; Soudais et al.,
2001). By identifying the cis-acting packaging domain of
adenoviruses infecting different species, we may be able to
identify different trans-acting factors involved in adenovi-
rus packaging, thus clarifying the general mechanism of
adenovirus packaging. In addition, availability of cis-acting
packaging domain of PAV-3 may help in the construction of
hybrid (PAV-3/HAV-5) gutless adenovirus vectors, thus
helping to eliminate or substantially reduce the helper virus
contamination. In the present study, we identified the pack-
aging domain of porcine adenovirus 3 (PAV-3) by con-
structing and analyzing packaging deletion mutants.
Results
Analysis of the PAV-3 genomic sequences
The cis-acting packaging domain of canine adenovirus-2
(Soudais et al., 2001) and most human adenoviruses (Grable
and Hearing, 1990, 1992; Hammarskjold and Winberg,
1980; Hearing et al., 1987; Kosturko et al., 1982; Schmid
and Hearing, 1997) appears to be located near the left end of
the genome between inverted terminal repeat (ITR) and the
start of E1A coding region. However, the position and
orientation of the packaging domain is not strict as long as
it is within the first or the last 600 bp of the genome
(Hammarskjold and Winberg, 1980; Hearing and Shenk,
1983; Hearing et al., 1987). The ITR of PAV-3 is 144 bp in
length (Reddy et al., 1998a). Based on the consensus se-
quences of cis-acting packaging motif of human adenovirus
5 [5-TTTGN8CG-3] (Schmid and Hearing, 1997), we
searched PAV-3 genome for putative cis-acting packaging
motifs in two regions of the viral genome (between left ITR
and E1A gene and between right ITR and E4 region). We
could not find any motif that showed perfect homology with
the consensus packaging motifs of HAV-5 between left ITR
and E1A gene or between right ITR and E4 region of
PAV-3 (Fig. 1). However, there are six AT/GC-rich motifs
between left ITR and E1A coding sequence of PAV-3 (Fig.
1). In addition, there are two AT/GC-rich motifs containing
“TTTG” sequence between right ITR and E4 region of
Fig. 1. Nucleotide sequence of PAV-3 termini. Numbers indicate the nucleotide position relative to the left terminus of PAV-3 genome. Inverted terminal
repeat (ITR) nucleotide sequence is shown in italic. (A) Nucleotide sequence of left terminus. The cap site A and ATG codon for E1A gene are shown in
italic bold case. AT-rich regions are in bold case. (B) Nucleotide sequence of PAV-3 right terminus. TTTG motif is shown in bold case.
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PAV-3 (Fig. 1). To characterize which of them could func-
tion in cis as packaging motifs for PAV-3 DNA, deletion
mutations were introduced into intact viral genome to delete
these candidate motifs in single fashion or in combinations.
Isolation of mutant viruses
To define cis-acting sequences required for packaging
PAV-3 DNA, initially, deletion mutations were constructed
in a recombinant transfer plasmid pPAV3.Eco47-3 (Fig.
2A) by replacing DNA sequences located between BamHI-
EcoRV restriction enzyme sites or between HpaI-PacI re-
striction enzyme sites with two PCR DNA fragments in a
three-way ligation. The individual deletions were then in-
troduced into intact viral genome (Fig. 2B) by homologous
recombination between wild-type PAV-3 genomic DNA
and Eco47-3-linearized individual recombinant transfer
plasmid in Escherichia coli BJ5183 cells (Chartier et al.,
1996). The PacI-digested individual full-length plasmid
DNA, transfected into VIDO R1 cells, produced cytopathic
effects (CPE) in 14 to 21 days. The infected cell monolayers
showing 50% cytopathic effects were collected and freeze-
thawed, and recombinant viruses were plaque purified and
propagated in VIDO R1 cells.
To confirm the presence of specific deletion(s), we ana-
lyzed the genomic DNA by PCR using primers generated
from the flanking regions of the deletions (Table 1). Mutant
viral DNAs were PCR amplified using primer pairs
PSR32-P2 for deletions between left ITR and E1A gene
(Fig. 3A, C, D, and E) or PR1-PSR32 for deletions between
E4 region and right ITR (Fig. 3B) and observed for a shift
in the size of their products generated due to deletions in the
mutants, compared to wild-type PAV-3 DNA (Fig. 3).
Compared to the wild-type PAV-3, all the deletion mutants
yielded the expected amplification products. Finally, the
identity of each deletion was confirmed by DNA sequence
analysis of the PCR fragments amplified using mutant viral
DNA(s).
Analysis of mutant viruses with internal deletions
Most of deletion mutations in this study were located
between nucleotide (nt) position 151 and 531, which also
contain the regulatory region of PAV-3 E1A transcription
unit (Reddy et al., 1998a). The mutation in this region could
probably affect the expression of E1A gene and thus result
in the changes in viral growth of mutant PAV-3, or even
make the virus nonviable. Since VIDO R1 cells could com-
plement the E1A defect of PAV-3 (Reddy et al., 1999b), this
cell line was used throughout this study.
Fig. 2. Schematic diagram showing isolation of mutant PAV-3. (A) Plasmid pPAV3.Eco47-3 used for producing deletion mutations. The left and right ITRs
of PAV-3 are indicated by filled boxes. PAV-3 sequences are from the extreme left (nt 1 to 2192) and right (nt 31499 to 34094) ends of the viral genome.
The E1A, E1B, and E4 coding regions, and their directions of transcription, are shown by filled arrows. (B). Strategy used for the construction of full-length
plasmid and isolation of mutant virus. The deletion mutations were created initially in the transfer plasmid pPAV3.Eco47-3 using PCR. Plasmid DNA (thin
line); PAV-3 genomic DNA (open box); ITR (filled box); deleted region (hatched boxes).
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To analyze the efficiency of packaging of the mutant
viral DNA, we used two assays. First, we determined the
yield of infectious virus in single infection on VIDO R1
cells by plaque assay. Since deletion of part of E1A
region of PAV-3 genome has been shown to lead to
reduced virus yield in VIDO R1 cells (Reddy et al.,
1999b), we also used a coinfection assay. In this assay,
VIDO R1 cells were coinfected with wild-type and mu-
tant PAV-3 at the same m.o.i. At 2 days after infection,
one-half of the cells were used to isolate the high-
molecular-weight nuclear DNA and the other half of the
cells were used to isolate the viral DNA from virion
particles (Grable and Hearing, 1990, 1992). The coinfect-
ing viral genomes could be distinguished by digestion of
viral DNA with MfeI and KpnI and by subsequent South-
ern hybridization analysis.
In the first set of mutant viruses, the small deletions
were targeted at the left (Fig. 4A; nt 151 to 531) and right
(Fig. 4A; nt 33911 to 33949) end of PAV-3 genome. As
seen in Fig. 4, the results of the single infection in VIDO
R1 cells showed that deletions extending from nt 151 to
213, 212 to 254, 252 to 313, 312 to 383, 432 to 449, and
461 to 497 resulted in two- to sevenfold reduction in the
yield of PAV-3. However, in coinfection assays (Fig.
4B), deletions extending from nt 151 to 213 and 461 to
497 had no effect on the packaging abilities of mutant
viruses (Fig. 4A). In addition, deletions extending from
382 to 433 had no effects on the yield of PAV-3 in single
infection as well as packaging ability of the virus in
coinfection assays (Fig. 4A). These results suggested that
these regions do not contain packaging motif(s). In con-
trast, the changes in packaging efficiency in coinfection
assays (Fig. 4B) were evident with mutant viruses contain-
ing deletions between nt 212 and 254 (Pav3-212/254), nt
252 and 313 (Pav3-252/313), nt 312 and 383 (Pav3-312/
383), nt 432 and 449 (Pav3-432/449), nt 447 and 474
(Pav3-447/474), and nt 495 and 531 (Pav3-495/531). How-
ever, the mutant viruses containing deletions between nt
33911 to 33949 at the right end of viral genome grew as
well as wild-type virus in VIDO R1 cells in single infection
(Fig. 4A). These results suggested that the packaging do-
mains of PAV-3 are (a) located at the left end of viral
genome, (b) possibly functionally redundant as described
for human adenovirus type 5 (Grable and Hearing, 1990;
1992; Schmid and Hearing, 1997), and (c) appeared to
overlap the promoter region of E1A gene.
Table 1
Primers used in PCR
Primer Sequencea PAV-3 nucleotide
positionb
Description
P1 5-CGT CTT CAA GGA TCC TTA-3 minus 23–minus 5 Sense, BamHI
P2 5-CGC GCT GAT ATC CTC CTC-3 827–844 Antisense, EcoRV
P3 5-CCG CAA TTG GTC ATC ACA CGT CAT TTT C-3 133–151 Antisense, MfeI
P4 5-CCG CAA TTG GGG GCG GGG CCG AGC GGC-3 213–230 Sense, MfeI
P5 5-CCG CAA TTG GCG GAG GAC CGC CCC AGG-3 195–212 Antisense, MfeI
P6 5-CCG CAA TTG ATA CCG CGG GAT TTT GT-3 255–271 Sense, MfeI
P7 5-CCG CAA TTG CTC CAC CTG TGC GGG AAT-3 235–252 Antisense, MfeI
P8 5-CCG CAA TTG CAC CAC ACG TCC GCG G-3 313–328 Sense, MfeI
P9 5-CCG CAA TTG CGG AAG TGC CAC ACC GGA-3 295–312 Antisense, MfeI
P10 5-CCG CAA TTG TCG CGC TGA GAG GTC CGC G-3 383–401 Sense, MfeI
P11 5-CCG CAA TTG AGG ACA CCC CGC TCA GGT-3 365–382 Antisense, MfeI
P12 5-CCG CAA TTG TTT TTT CCC CTC AGT GTA TA-3 433–452 Sense, MfeI
P13 5-CCG CAA TTG TAC ACC CAC ACA CGT CAT-3 415–432 Antisense, MfeI
P14 5-CCG CAA TTG TAT ATA GTC CGC GCA-3 449–463 Sense, MfeI
P15 5-CCG CAA TTG ACT GAG GGG AAA AAA TAC-3 430–447 Antisense, MfeI
P16 5-CCG CAA TTG GTC ACT ACT CTT GAG TCC-3 474–491 Sense, MfeI
P17 5-CCG CAA TTG CGC GGA CTA TAT ACA CTG-3 444–461 Antisense, MfeI
P18 5-CCG CAA TTG GAG TAG AGT TTT CTC TCA-3 497–514 Sense, MfeI
P19 5-CCG CAA TTG CTT CGG ACT CAA GAG TAG-3 478–495 Antisense, MfeI
P20 5-CCG CAA TTG ACA TGG CGA ACA GAC TTC-3 531–548 Sense, MfeI
PR1 5-CCG CCT CCG CGT TAA CGA TTA ACC-3 33838–33861 Sense, HpaI
PR2 5-AGC TTT TAA TTA ACA TCA TC-3 34088–34094 Antisense, PacI
PR3 5-CCG CAA TTG CGC AGG TCG CGG CGG AGC-3 33894–33911 Antisense, MfeI
PR4 5-CCG CAA TTG CCT CGG ACT TTG ACC GT-3 33926–33942 Sense, MfeI
PR5 5-CCG CAA TTG GGC GGG GTC AAA GTC GCA-3 33908–33926 Antisense, MfeI
PR6 5-CCG CAA TTG CCA CGT CAT TTT CCC A-3 33949–33965 Sense, MfeI
PSR32 5-CGG CGG GAT CCT TAA TTA ACA TCA TCA ATA ATA TAC CGC ACA CTT TT-3 1–18
a The restriction endonuclease cleavage sites are underlined.
b Numbers indicate the nucleotide position relative to the left terminus of PAV-3 (Reddy et al., 1998b) genome. PAV-3 nucleotide sequences are indicated
in boldface type.
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Analysis of mutant viruses with progressive deletions
To further define the packaging domain of PAV-3, we
constructed two additional sets of mutant viruses. One set of
mutant viruses contains deletions, which progress from a
common site at nt 151 toward the downstream border of the
packaging domain (Fig. 5A). As seen in Fig. 5, mutant
Pav3-151/254 carrying deletion between nt 151 and 254 had
a twofold reduction in virus yield in single infection and a
twofold reduction in the packaging ability in coinfection
assays. The sequential additional deletions from nt 254 to
313 (Pav3-151/313) and 313 to 383 (Pav3-151/383) resulted
in a five-to eightfold reduction in viral yields in single
infection, and three-to sevenfold reduction in packaging
ability in coinfections, respectively. These results suggested
that there are packaging motifs located between nt 254 and
313 and nt 313 and 383. The additional deletions extending
from nt 383 to 497 (Pav3-151/433, Pav3-151/449, Pav3-
151/474, Pav3-151/497) did not result in the further signif-
icant reduction in viral growth in single infection and in
packaging ability in coinfection assays. Although deletion
from nt 497 to 531 is not lethal, deletion extending from nt
151 to 531 (Pav3-151/531) resulted in the loss of virus
viability, suggesting that the sequence between nt 497 to
531 contains a packaging motif which alone can support the
packaging of PAV-3. This motif probably represented the
downstream border packaging motif. Surprisingly, the mu-
tant with a deletion between nt 151 and 449 (Pav3-151/449)
showed 20-fold reduction in the virus yield in VIDO R1
cells in a single infection. The reasons for this phenomenon
remain unclear.
A second set of viral mutants was constructed which
contained unidirectional deletions progressing from a com-
mon site at nt 531 toward the upstream border of the
packaging domain (Fig. 6A). As seen in Fig. 6A, we could
not isolate a viable mutant PAV-3 when deletions extended
from nt 531 to 212 (Pav3-212/531). The results suggested
that the packaging domain of PAV-3 existed between nt 212
and 531. The addition of DNA sequences between nt 212
and 252 (Pav3-252/531) made the virus viable, suggesting
that there exists a packaging motif in this region, which
alone can make the mutant virus viable (Figs. 6A and B).
Fig. 3. Genomic PCR of viral mutants. PCR amplified products generated by primer pair PSR32-P2 (A,C,D,E) or PSR32-PR1 (B) flanking the individual
deletions are shown in comparison to PCR products generated by amplification of the same region from wild- type PAV-3 DNA. The expected sizes of
amplified products generated by PCR from wild-type PAV-3 and mutant viruses are shown at the bottom. Molecular size markers are indicated on the left.
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Fig. 4. Analysis of viral mutants carrying individual deletions. (A) Schematic view of viral mutants. The top of the figure shows the position of AT/GC-rich
motifs (filled box); E1A cap site (filled circle) and E1A ATG (arrow head), and structure of the left terminus of PAV-3 genome. The individual deletion
mutant names are given on the left. The nucleotide numbers correspond to the first nucleotides present on either side of the deletion. The deleted sequences
are indicated by dotted line. Mutant virus yields (YIELD) are expressed as the fold reduction in yield relative to that of wild-type virus. Mutant virus
packaging efficiency (COINF) is expressed as the fold reduction in packaged mutant DNA relative to the packaged coinfecting wild-type DNA. The data were
normalized to the amount of each viral DNA (mutant and wild-type) present in total DNA. NT, not tested. (B) Southern hybridization analysis of viral DNA
represented either in total DNA or in virion particles isolated from VIDO R1 cells coinfected with wild-type and the mutant viruses. Total nuclear DNA and
virion DNA were digested with MfeI and KpnI and subsequently subjected to Southern hybridization analysis using PAV-3 left-end and fragment between
nt 531 and 844 as a [32P]-labeled probe. The corresponding wild-type (WT) and mutant (MU) left-end DNA fragments are indicated. The mutant viruses tested
were Pav3-151/213 (lane 1), Pav3-212/254 (lane 2), Pav3-252/313 (lane 3), Pav3-312/383 (lane 4), Pav3-382/433 (lane 5), Pav3-432/449 (lane 6),
Pav3-447/474 (lane 7), Pav3-461/497(lane 8), Pav3-495/531(lane 9). (C) Results of the phosphoimager scanning of DNA band intensity are shown.
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This motif represented the upstream border of the packaging
domain of PAV-3. The sequential addition of DNA se-
quences between nt 252 and 382 (Pav3-312/531, Pav3-382/
531) resulted in a five- to ninefold increase in the yield and
a one- to fourfold increase in the packaging ability com-
pared with that of mutant virus Pav3-252/531 (Figs. 6A and
B). These results suggested that there appears to be two
packaging motifs located between nt 252 and 382. The
addition of DNA sequences between nt 382 and 432 (Pav3-
432/531) had no effect either on the yield or on the pack-
aging ability of PAV-3. However, the addition of DNA
sequences between nt 432 and 447 resulted in onefold
increase in the virus yield and twofold increase in the
packaging ability when compared with that of Pav3-432/
531, suggesting that a packaging motif exists between nt
432 and 447 (Figs. 6A and B). Although there was no
difference in the yield of Pav3-447/531 and Pav3-461/531
in single infection, addition of nt 447 to 461 resulted in a
onefold increase in the packaging ability of Pav3-461/531.
This suggested that nt 447 to 461 may contain a packaging
motif.
Although Pav3-151/449, Pav3-151/433, and Pav3-151/
474 showed comparable packaging ability in coinfection
assays (Fig. 5), Pav3-151/449 showed a two and one-half
fold more reduction in virus yield than Pav3-151/433 or
Pav3-151/474 in single infection of VIDO R1 cells. To
reconfirm these observations, we constructed another set of
mutants with deletions progressing from a common site at nt
449 toward the upstream border of packaging domain at nt
212 (Fig. 7A). The sequential addition of DNA sequences
between nt 212 and 252 (Pav3-252/449), 252 and 312
(Pav3-312/449), and 312 and 382 (Pav3-382/449) increased
the packaging ability of PAV-3 correspondingly in a coin-
fection assay (Fig. 7A and B). These data are in agreement
with that described above (Fig. 5) and confirm that packag-
ing motifs exist in these three regions. In contrast, there was
still significant reduction in the yield of Pav3-212/449 and
Pav3-252/449 in VIDO R1 cells in a single infection assay
(Fig. 7A). However, the addition of DNA sequences be-
tween nt 252 and 312 enhanced significantly the viral
growth in VIDO R1 cells, although it made the viral pack-
aging ability increase slightly. These data suggested that
DNA sequences between nt 252 and 312 may have other
unknown functions in viral life cycle which significantly
affect the yield of the PAV-3.
Discussion
Adenoviruses appear to package its DNA in preformed
empty capsids (D’Halluin et al., 1978a, 1978b, 1980; Ed-
vardsson et al., 1976, 1978) by recognition of specific viral
sequences by viral and cellular packaging proteins (Fuji-
sawa and Hearing, 1994; Grable and Hearing, 1992; Schmid
and Hearing, 1995, 1998). Although the identity of viral and
cellular proteins that interact with packaging domain is
becoming clear (Gustin and Imperiale, 1998; Hasson et al.,
1989; Schmid and Hearing, 1998; Zhang et al., 2000, 2001),
the cis-acting packaging sequences appear to be conserved
among the subgroups of human adenoviruses (Schmid and
Hearing, 1997). However, the primary sequence of the cis-
acting packaging motif(s) of CAV-2 (nonhuman adenovi-
rus) appears to be different, suggesting that viral elements
involved in the DNA packaging might have adapted to
interact with species-specific cellular factors (Soudais et al.,
2001). Here, we describe the construction and characteriza-
tion of packaging mutants, and the sequence motifs that
appear to direct PAV-3 packaging.
Although cis-acting packaging domain of adenoviruses
appears to be located near the left end of the genome, it can
also be functional even when present in the last 600 bp of
the right end of adenovirus genome (Hammarskjold and
Winberg, 1980; Hearing and Shenk, 1983; Hearing et al.,
1987). Interestingly, analysis of the right end of PAV-3
genome identified two motifs containing first element (5-
TTTG-3) of consensus sequence of cis-acting packaging
motif of HAV-5 (Schmid and Hearing, 1997). Similar mo-
tifs have been shown to be part of the cis-acting packaging
domain of CAV-2 (Soudais et al., 2001). However, mutant
PAV-3s containing deletion of one or both motifs (5-
TTTG-3) grew as well as wild-type virus, suggesting that
these motifs are not involved in the packaging of PAV-3
genome. In contrast, analysis of PAV-3 mutants containing
deletions in the left end of PAV-3 identified functional
cis-acting packaging domain to 319 bp (nt 212 to 531),
which showed no sequence homology to bipartite packaging
motif of HAV-5 (Schmid and Hearing, 1997). Additionally,
aside from AT/GC-rich character, none of the potential
packaging motifs showed any primary sequence homology.
These results confirm earlier observations (Soudais et al.,
2001) and further suggest that primary sequence require-
ments for packaging motif(s) may be different for adenovi-
ruses of different species.
Of the five known PAV serotypes (Derbyshire et al.,
1975; Hirahara et al., 1990), DNA sequences of only PAV-3
(Reddy et al., 1998a,b) and PAV-5 (Nagy et al., 2001) are
known. Analysis of the left end of PAV-5 genome does not
contain putative cis-acting packaging motifs identified in
HAV-5 (Schmid and Hearing, 1997) and CAV-2 (Soudais et
al., 2001). In contrast, we could identify AT/GC-rich motifs
between left ITR and ATG of E1A of PAV-5 genome.
Interestingly, the number and organization of these AT/GC-
rich motifs appear similar to those identified in PAV-3
(Table 2), suggesting that other porcine adenoviruses may
have identical cis-acting packaging motifs. Although more
data are required to draw a conclusion, it appears that
adenoviruses infecting the same host may have similar
packaging motifs, which will allow them to interact with
viral and host-specific cellular factors.
PAV-3 packaging domain contains six AT/GC-rich ele-
ments, one of which contains consensus sequence (5-
TTTG-3) of cis-acting packaging domain of CAV-2 (Sou-
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dais et al., 2001). Interestingly, another packaging motif
overlaps the TATA box (nt 449–454) of the E1A promoter.
Although the AT/GC-rich motifs appear to be functionally
redundant and have additive effect on the packaging effi-
ciency, these motifs (individual or combination) do not
appear to be functionally equivalent in VIDO R1 cells.
These results are consistent with the suggestions that dif-
ferent packaging factors may interact with different pack-
aging motifs depending upon the type of cells infected
(Soudais et al., 2001).
Fig. 5. Analysis of viral mutants carrying progressive deletions with a common start site at nt 151. (A) The schematic, mutant names, endpoints of the deletion,
and in vivo packaging analysis are as described in the legend to Fig. 4A. (B) Southern hybridization analysis of total and virion DNA isolated from VIDO
R1 cells coinfected with wild-type and individual mutant viruses. Southern hybridization analysis of total DNA and virion DNA was performed as described
in the legend to Fig. 4B. The mutant viruses tested were Pav3-151/254 (lane 1), Pav3-151/313 (lane 2), Pav3-151/383 (lane 3), Pav3-151/433 (lane 4),
Pav3-151/449 (lane 5), Pav3-151/474 (lane 6), Pav3-151/497 (lane 7). NV, nonviable virus.
Fig. 6. Analysis of viral mutants carrying progressive deletions with a common start site at nt 531. (A) The schematic, mutant names, endpoints of the deletion,
and in vivo packaging analysis are as described in the legend to Fig. 4A. (B) Southern hybridization analysis of total and virion DNA isolated from VIDO
R1 cells coinfected with wild-type and individual mutant viruses. Southern hybridization analysis of total DNA and virion DNA was performed as described
in the legend to Fig. 4B. The mutant viruses tested were Pav3-252/531(lane 1), Pav3-312/531 (lane 2), Pav3- 382/531 (lane 3), Pav3-432/531 (lane 4),
Pav3-447/531(lane 5), Pav3-461/531 (lane 6). NV, nonviable virus.
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Several mutant viruses exhibited an unexpected decrease
in the virus yield in a single infection. As these mutant
viruses showed comparable packaging capacity in coinfec-
tion experiments with wild-type PAV-3, the defect appeared
to be in the absence of a trans-acting factor(s). Our results
suggest that a cis-acting element required for this effect is
located between nt 252 and 312. In HAV-5, the cis-acting
packaging domain overlaps two distinct transcriptional en-
hancer elements. Element I specifically stimulates E1A
transcription (Hearing and Shenk, 1986) upon binding of a
cellular factor EF1A (Bruder and Hearing, 1989). Element I
mutants can be efficiently complemented in single infection
by propagation of virus in E1-expressing cells (e.g., 293
cells) (Graham et al., 1977). In contrast, element II enhances
transcription from all early transcription units. Element II
mutants can be efficiently complemented in trans by pro-
viding all of the gene products in a mixed infection with
wild-type virus (Hearing and Shenk, 1986). Although the
nature of the defect in these PAV-3 mutants is not known,
it is possible that this region may regulate viral gene ex-
pression similar to the enhancer element II of HAV-5 E1A
transcription unit (Hearing and Shenk, 1983, 1986).
Some mutant HAV-5 (Grable and Hearing, 1990) or
CAV-2 (Soudais et al., 2001) viruses showed dramatic re-
duction in the virus yield in single infections or coinfec-
tions. In contrast, the effects of most of the deletion muta-
tions on mutant PAV-3 yield ranged from 2- to 20-fold
except on two nonviable mutant PAV-3s. It is possible that
a functionally intact packaging motif(s) critical for DNA
packaging is present in these mutants. Alternatively, the
effect of spatial changes between individual packaging mo-
tifs may not affect virus yield in PAV-3 as severely as
observed in HAV-5 (Schmid and Hearing, 1997).
Knowledge of requirements of DNA packaging of
PAV-3 has important implications for the development of
improved gutless adenovirus gene transfer vectors. Gutless
or helper-dependent adenovirus vectors have demonstrated
great promise in reducing the host immune response against
virus encoded proteins and extending the expression of
therapeutic gene (Balague et al., 2000; Chen et al., 1997;
Cregan et al., 2000; Kim et al., 2001; Maione et al., 2000;
Morral et al., 1998,1999; Morsy et al., 1998; Oka et al.,
2001; Schiedner et al., 1998; Thomas et al., 2000; Zhou et
al., 2001). Although a number of approaches have been
developed to make gutless adenovirus vectors (Ng et al.,
2001; Parks et al., 1996; Sandig et al., 2000; Umana et al.,
2001; Zhou et al., 2001), all of them still leave a significant
level of helper virus contamination. Based on the availabil-
ity of cis-acting packaging domain of PAV-3, and the
growth properties of PAV-3 in human cells, a system can be
developed where vector DNA is specifically packaged. In
this system, helper vector (containing PAV-3 packaging
domain) and recombinant vector (containing PAV-3 and
Fig. 7. Analysis of viral mutants carrying progressive deletions with a common start site at nt 449. The schematic, mutant names, endpoints of the deletion,
and in vivo packaging analysis are as described in the legend to Fig. 4A. (B) Southern hybridization analysis of total and virion DNA isolated from VIDO
R1 cells coinfected with wild-type and individual mutant viruses. Southern hybridization analysis of total DNA and virion DNA was performed as described
in the legend to Fig. 4B. The mutant viruses tested were Pav3-212/449 (lane 1), Pav3-252/449 (lane 2), Pav3- 312/449 (lane 3), and Pav3-382/449 (lane 4).
Table 2
Alignment of potential packaging motifs of PAV-3 and PAV-5
Virus Packaging
motif
Sequencea A/T
nucleotideb
PAV-3 I GCGG AAATT CCCG 233–237
II CGGG ATTTT GTGC 264–268
III CCGG TATT CCCC 334–337
IV GGTG TATTTTTT CCCC 431–438
V AGTG TATATA GTCC 449–454
VI AGAG TTTT CTCT 505–508
PAV-5 I CTGG TATTTT CCAC 187–192
II TGTG ATATT GGAC 207–211
III GACC TTTA CCTG 217–220
IV ACTC AATTTTA CCAC 271–277
V GTCG ATTTTT CCAC 321–326
VI TCCC TATTTATT CTGC 349–356
a AT-rich sequences are indicated in boldface type.
b Numbers indicate the nucleotide position relative to the left terminus of
PAV-3 (Reddy et al., 1998b) or PAV-5 (Nagy et al., 2001) genomes.
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HAV-5 packaging domains) will be transfected into porcine
cells infected with PAV-3, leading to the production of three
types of viral particles. This mixture can be used to infect
human cells which will only package genomes containing
HAV-5 packaging domain, thus helping to eliminate or
substantially reduce the helper virus contamination.
Materials and methods
Cells and viruses
VIDO R1 cells (HAV-5 E1-expressing fetal porcine ret-
ina cells) (Reddy et al., 1999b) were grown and maintained
in Eagle’s minimum essential medium (MEM) supple-
mented with 10% fetal bovine serum (FBS). The wild-type
(6618 strain) (Clarke et al., 1967) and mutant PAV-3s were
propagated and titrated in VIDO R1 cells.
Construction of recombinant plasmids
A 6.814-kb Eco47-3 fragment [containing vector back-
bone plus the left (nt 1–2192) and right (nt 31499–34094)
termini of the PAV-3 genome] isolated from pFPAV200
(Reddy et al., 1999a) was religated, creating plasmid
pPAV3.Eco47-3 (Fig. 2A). Nucleotide numbers of the
PAV-3 genome referred to in this article are given accord-
ing to GenBank Accession No. AF083132. This plasmid
DNA containing both the ends of PAV-3 genome was used
as template in PCR amplifications using specific primers
(Table 1) to create specific deletion between left ITR and
ATG of E1A gene (Reddy et al., 1998b). The following
conditions were used for PCR in a total volume of 50 l: 0.5
g of template DNA, 1 PCR buffer [10 mM KCl, 10 mM
(NH4)2SO4, 20 mM Tris–Cl (pH 8.75), 2 mM MgSO4, 0.1%
Triton X-100, 0.1 mg/ml BSA; Stratagene], 0.4 mM dNTPs,
10 pmol of each primer, 2.0 U of cloned pfu DNA poly-
merase (Stratagene). The cycling conditions were 94°C for
2 min to denature the DNA, followed by 30 cycles consist-
ing of 94°C for 40 s, 50°C for 40 s, 72°C for 40 s, and
finally, extention at 72°C for 2 min. The products of PCR
were separated on a 2% agarose gel and visualized by
ethidium bromide (EtBr) staining.
To construct recombinant transfer plasmids containing
the deletions between left ITR and ATG of E1A gene of
PAV-3 (Reddy et al., 1999b), first the DNA fragments
amplified using primer pairs P1-P3, P1-P5, P1-P7, P1-P9,
P1-P11, P1-P13, P1-P15, P1-P17, and P1-P19 were digested
with BamHI and MfeI. Second, the DNA fragments ampli-
fied using primer pairs P2-P4, P2-P6, P2-P8, P2-P10, P2-
P12, P2-P14, P2-P16, P2-P18, P2-P20 were digested with
MfeI and EcoRV. The appropriate BamHI-MfeI and MfeI-
EcoRV DNA fragments were ligated to BamHI-EcoRV-
digested pPAV3.Eco47-3 in a three-way ligation, thus cre-
ating the recombinant transfer plasmids containing the
desired deletions between left-end ITR and ATG codon of
E1A gene of PAV-3 (Figs. 4A, 5A, 6A, and 7A).
To construct the recombinant plasmids containing the
deletions between right-end ITR and E4 gene of PAV-3,
first the DNA fragments amplified using primer pairs PR1-
PR3 and PR1-PR5 were digested with HpaI and MfeI.
Second, the DNA fragments amplified using primer pairs
PR2-PR4 and PR2-PR6 were digested with MfeI and PacI.
The appropriate HpaI-MfeI and MfeI-PacI DNA fragments
were ligated to HpaI-PacI-digested pPAV3.Eco47-3 in a
three-way ligation, thus creating the recombinant transfer
plasmid(s) containing desired deletions between E4 and
right-end ITR (Fig. 4A).
The plasmids containing the full-length genome of
PAV-3 with deletions in the putative packaging domain
were generated by homologous recombination in E. coli
BJ5183 (Chartier et al., 1996) between Eco47-3-linearized
individual recombinant transfer plasmid and the genomic
DNA from wild-type PAV-3 (Fig. 2B). These plasmids
were characterized by restriction endonuclease analysis.
The endpoints of deletion plasmids containing the desired
deletions between E4 and the right ITR (Fig. 4A) were
determined by nucleotide sequence analysis.
Isolation of PAV-3 mutants
VIDO R1 cell monolayers were seeded in a 35-mm-
diameter dish and were transfected with 5 g of PacI-
digested individual full-length plasmid DNA using the Li-
pofectin methods according to the instructions of
manufacturer (Invitrogen). After 10 to 15 days of incubation
at 37°C, the transfected cells were collected and freeze
thawed three times. The lysates were used to infect the
freshly prepared VIDO R1 cells until cytopathic effect ap-
peared. Finally, the recombinant viruses were characterized
by PCR and restriction analysis and then expanded and
titrated on VIDO R1 cells.
Determination of virus yields and packaging efficiency
All viral infections were performed at an multiplicity
of infection (m.o.i.) of 5 plaque-forming units (PFU) per
cell at 37°C for 1 h. The cells were washed and fresh
medium was added. For the determination of viral yield
in single-virus infections, infected VIDO R1 cells were
harvested 48 h after infection and then lysed by three
cycles of freezing and thawing. The infectious virus
yields in cleared lysates were determined by plaque assay
on VIDO R1 cells. The data presented for virus yields
from single infections represent the averages of three
independent experiments.
Packaging efficiency of the mutant viruses was deter-
mined by coinfection of VIDO R1 cells with both the
mutant and the wild-type PAV-3, according to the method
described earlier (Grable and Hearing, 1990, 1992), with
little modification. VIDO R1 cells were infected with 5 PFU
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of each of the viruses per cell as described above. Forty-
eight hours postinfection, one-half of the cells were used to
isolate high-molecular-weight DNA, and the other half of
the cells were used to prepare viral DNA from virions. For
the isolation of infected cell high-molecular-weight DNA,
the cells were lysed by the addition of Nonidet P-40 to
0.4%, and then digested with proteinase K at 50°C for at
least 2 h. The high-molecular-weight DNA was isolated as
described previously (Sambrook et al., 1989). For the iso-
lation of viral DNA from virions, infected cells were pel-
leted and suspended in lysis buffer [20 mM Tris–Cl (pH
8.0), 0.2% deoxycholate, 10% ethanol]. After incubation for
60 min at room temperature, the lysate was cleared at
10,000 g for 30 min. The supernatant was adjusted to 2 mM
CaCl2 and 2 mM MgCl2, and was digested with 40 g of
RNase A per milliliter and 10 g of DNase I per milliliter
at 37°C for 30 min. The reaction was stopped by the addi-
tion of EDTA and EGTA to a final concentration of 50 mM
each. Virus particles were lysed by the addition of Sarkosyl
to 0.5%, and the samples were digested with 1 mg of
proteinase K per milliliter at 50°C for 1 to 2 h. After phenol
and chloroform extraction, the viral DNA was precipitated
with ethanol. The DNAs isolated from cells or virions were
digested with MfeI and KpnI and then analyzed by Southern
hybridization.
Southern hybridization
The MfeI- and KpnI-digested DNAs were separated on
1.5% agarose gel and then transferred to Gene Screen Plus
hybridization transfer membrane (Perkin–Elmer Life Sci-
ence) by high salt capillary transfer method according to the
instructions of the manufacturer. The 314-bp DNA frag-
ment corresponding to nt 531–844 was amplified by PCR
with primers P2 and P20, labeled with [32P]-dCTP by the
random primer method using Random Primers DNA label-
ing system (Invitrogen), and used as a probe in Southern
hybridization analysis. The blots were prehybridized in
ULTRAhyb ultrasensitive hybridization buffer (Ambion
RNA) at 42°C for 30 min, and then [32P]- labeled probes
were added. Hybridization was performed at 42°C over-
night. After extensively washing with 0.1 SSC and 0.1%
SDS, the blots were exposed to X-ray film (Kodak) without
an intensifying screen. The bands in autoradiograms were
scanned and their relative intensities were determined and
analyzed by Computing Densitometer using phosphoimager
program. The data presented for packaging efficiency based
on coinfection experiments represent the averages of three
independent experiments.
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